Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mynberrys Compound is a nutritional and protein supplement syrup developed by Juggat Pharma (a division of Jagdale Industries). It is formulated with a combination of proteolysed liver extract, proteolysed meat extract, ovolecithin, ferrous gluconate, creosote, and guaiacol. The supplement is indicated for the treatment of weakness, protein malnutrition, tuberculosis (T.B.), and pulmonary diseases, as well as for supportive care during convalescence and acute or chronic bacterial infections. The proteolysed liver and meat extracts provide highly bioavailable proteins, amino acids, and B vitamins, while ferrous gluconate supports red blood cell production. Creosote and guaiacol contribute antioxidant, anti-inflammatory, antiseptic, and expectorant properties to support respiratory health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mynberrys Compound.